Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Jan Philipp Bewersdorf, Amer M. Zeidan
Topics & Concepts
DecitabineAzacitidineMedicineHypomethylating agentMyelodysplastic syndromesVenetoclaxOncologyInternal medicineLenalidomideIntensive care medicineSalvage therapyLeukemiaChemotherapyBone marrowDexamethasoneChronic lymphocytic leukemiaGene expressionGeneDNA methylationBiochemistryChemistryAcute Myeloid Leukemia ResearchPneumocystis jirovecii pneumonia detection and treatmentImmunodeficiency and Autoimmune Disorders